Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 28, Issue 2, 1999, Pages 214-216

  Weinstein, Toba A ^a   Sciubba, James J ^b   Levine, Jeremiah ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADOLESCENT; APHTHOUS ULCER; ARTICLE; CASE REPORT; COLON CROHN DISEASE; DIAGNOSTIC APPROACH ROUTE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; MOUTH DISEASE; MOUTH ULCER; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; CROHN DISEASE; FEMALE; HUMANS; ORAL ULCER; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032975429     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199902000-00025     Document Type: Article

References (23)

1. Basu MK, Asquith P, Thompson RA, Cooke WT. Oral manifestations of Crohn's disease. Gut 1975;16:249-54.
2. Greenstein AZ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine 1976;55:401-12.
3. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn's disease. J Clin Gastroenterol 1991;13:29-37.
4. Present DH. Extraintestinal manifestations. Mt Sinai J Med 1983; 50:126-32.
5. Rankin GB. Extraintestinal and systemic manifestations of inflammatory bowel disease. Med Clin North Am 1990;74:39-50.
6. Allan RN. Extra-intestinal manifestations of inflammatory bowel disease. Clin Gastroenterol 1983;12:617-32.
7. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985;12:85-90.
8. Grinspan D, Blanco GF, Aguero S. Treatment of aphthae with thalidomide. J Am Acad Dermatol 1989;20:1060-3.
9. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990;126:923-7.
10. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
11. Nicolau DP, West TE. Thalidomide: Treatment of severe recurrent aphthous stomatitis in patients with AIDS. DICP Ann Pharmacother 1990;24:1054-56.
12. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995;20: 250-4.
13. Soler RA, Migliorati C, vanWaes H, Nadal D. Thalidomide Treatment of mucosal ulcerations in HIV infection. Arch Dis Child 1996;74:64-5.
14. Lloyd-Still JD, Green OC. A clinical scoring system for chronic inflammatory bowel disease in children. Dig Dis Sci 1979;24: 620-4.
15. Sampaio EP, Sarno EN, Galilly R, Cohn AZ, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
16. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994;91:4082-5.
17. New uses of thalidomide. Med Lett Drugs Ther 1996;38:15-16.
18. Mennis S, Imondi D, Brancaleone W, Croci S. Recurrent giant aphthous ulcers in a child: Protracted treatment with thalidomide. Pediatr Dermatol 1993;10:283-5.
19. Odeka EB, Miller V. Thalidomide in oral Crohn's disease refractory to conventional medical treatment (letter). J Pediatr Gastroenterol Nutr 1997;25:250-1.
20. Waters MF, Laing AB, Ambikapathy A. Treatment of ulcerative colitis with thalidomide (letter). BMJ 1979;1:792.
21. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. The Lancet 1997;350:1445-6.
22. Targan SR, Hanauer SB, vanDeventer SJH, Mayer L, Present D, et al. A short-term study of chimeric monoclonal antibody CA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337:1029-35.
23. vanDullemen HM, vanDeventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (CA2). Gastroenterology 1995;190:129-35.